GABA signalling in human pancreatic islets

Front Endocrinol (Lausanne). 2023 Feb 20:14:1059110. doi: 10.3389/fendo.2023.1059110. eCollection 2023.

Abstract

The pancreatic islets are essential microorgans controlling the glucose level in the blood. The islets consist of different cell types which communicate with each other by means of auto- and paracrine interactions. One of the communication molecules produced by and released within the islets is γ-aminobutyric acid (GABA), a well-known inhibitor of neuronal excitability in the mammalian nervous system. Interestingly, GABA is also present in the blood in the nanomolar concentration range. Thus, GABA can affect not only islet function per se (e.g. hormone secretion) but also interactions between immune cells and the pancreatic islet cells in physiological conditions and in pathological states (particularly in type 1 diabetes). In the last decade the interest in GABA signalling in islets has increased. The broad research scope ranges from fundamental physiological studies at the molecular and cellular level to pathological implications and clinical trials. The aim of this mini-review is to outline the current status of the islet GABA field mostly in relation to human islets, to identify the gaps in the current knowledge and what clinical implications GABA signalling may have in islets.

Keywords: GABA tolerance; GABAA receptor; T1D mouse model; blood glucose; diabetes mellitus; insulin secretion; mixed-identity cell; β cell.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 1* / metabolism
  • Humans
  • Islets of Langerhans* / metabolism
  • Mammals / metabolism
  • Signal Transduction
  • gamma-Aminobutyric Acid / metabolism

Substances

  • gamma-Aminobutyric Acid

Grants and funding

The work was supported by the Swedish Research Council, Diabetes Research and Wellness Foundation, Swedish Child Diabetes Foundation, the Novo Nordisk Foundation, the Swedish Child Diabetes Foundation, Family Ernfors Foundation, the strategic grant consortium Excellence of Diabetes Research in Sweden (EXODIAB), E. Wessler’s Foundation and Astrid Karlsson’s Foundation for medical research (Uppsala University) and Thurings Foundation.